Clene Inc. has risen 17.06% over the past month, closing at $11.22 on June 15. During this period of time, the stock fell as low as $10.09 and as high as $12.07. CLNN has an average analyst recommendation of Strong Buy. The company has an average price target of $22.25. Clene Inc. has gained Tuesday morning, with the stock adding 27.30% in pre-market trading to $16.30.
Clene Inc., a biopharmaceutical company focused on the discovery and development of innovative cellular-based medicines for the treatment of neurodegenerative diseases, today announced that it will host a webinar on July 14, 2021. The speakers will discuss the current state of the treatment and unmet medical needs for people with sclerosis and amyotrophic lateral sclerosis. Clene will also provide an overview of its lead product candidate, CNM-Au8.
Clene’s lead candidate is CNM-Au8, a stable, aqueous suspension of gold nanocrystals that can improve cellular energy and reduce oxidative stress. Investors will also hear about the company’s pipeline and upcoming milestones. Clene is a clinical-stage biotechnology company focused on the development of bioenergetic drugs to treat central nervous system (CNS) diseases.
Finance and Entertainment Reporter
Richard is a bottle of wine – the older the sweeter. He has already found the sweetest hobby in writing entertainment and finance news for Own Snap. Readers get the updated posts regularly from him searching for real-time news.